Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio

About Fujirebio Diagnostics

Fujirebio is a well-established, R&D-driven diagnostics company and a significant player in the global IVD market, particularly known for its pioneering work in blood-based biomarkers for Alzheimer's disease. Its business model combines the development and sale of its own diagnostic instruments and assays with a robust Contract Development and Manufacturing Organization (CDMO) service, providing raw materials, reagents, and full development services to partners. Backed by its parent company H.U. Group, Fujirebio reinvests partnership revenues into R&D to fuel a continuous pipeline of innovative diagnostic content, aiming to expand access to advanced testing worldwide.

Therapeutic Areas

Other Alzheimer's Disease (Amyloid Pathology) Drugs